人类分泌因子受体亚二醇激动剂的结构-活性关系
Robert Ardecky1, Daniela G Dengler1, Kaleeckal G Harikumar2
1From Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
SLAS discovery : advancing life sciences R & D
|August 9, 2024
概括
研究人员确定了一种新型的小分子激素对秘受体的激动剂,这是对心血管,胃肠道和代谢疾病的潜在治疗方法. 这种化合物表现出增强的活性和稳定性,为新的口服疗法铺平了道路.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 秘素受体激动剂对心血管,胃肠道和代谢疾病具有治疗潜力.
- 目前,没有经过临床批准的非类分泌素受体激活剂可用.
研究的目的:
- 为了识别和表征新型的小分子激素 secretin受体的激素.
- 为了探索基于亚二醇的支架的结构-活性关系,用于秘密因子受体激动.
主要方法:
- 一个系统的结构-活动系列的合成和表征,围绕着一个亚二醇支架.
- 在体外评估化合物的活性和特异性.
- 使用肝脏显微体评估血稳定性和代谢概况.
主要成果:
- 鉴定出了一种新型的小分子化合物,具有秘密素受体激动剂活性.
- 结构-活性关系研究增强了体外活性,并保持了特异性.
- 最活跃的化合物表现出血稳定性,但被肝脏显微体代谢.
结论:
- 已识别的亚二醇衍生物代表了体外研究的一个有前途的化学探针.
- 进一步的体内测试是有必要的,以评估药理活性.
- 这项工作为开发一流的,口服活跃的分泌素受体激动剂用于各种疾病状态的基础.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
914
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
914
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
548
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
548
Structure-Activity Relationships and Drug Design
687
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
687
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.1K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.1K
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311


